Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis.
Title | Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. |
Publication Type | Journal Article |
Year of Publication | 2012 |
Authors | Momah, N., Silveira M. G., Jorgensen R., Sinakos E., & Lindor K. D. |
Journal | Liver Int |
Volume | 32 |
Issue | 5 |
Pagination | 790-5 |
Date Published | 2012 May |
ISSN | 1478-3231 |
Keywords | Alkaline Phosphatase, Ascites, Bilirubin, Biomarkers, Cholagogues and Choleretics, Clinical Trials as Topic, Disease Progression, Endpoint Determination, Female, Hepatic Encephalopathy, Humans, Liver Cirrhosis, Biliary, Liver Transplantation, Male, Middle Aged, Multicenter Studies as Topic, Retrospective Studies, Treatment Outcome, Ursodeoxycholic Acid, Varicose Veins |
Abstract | BACKGROUND: Biochemical tests have been recommended as endpoints for clinical trials in primary biliary cirrhosis (PBC) because the use of liver transplantation and death as endpoints in ursodeoxycholic acid (UDCA) therapeutic trials is unfeasible. The best inclusion criteria cut-off values and cut-off for demonstrating treatment success have not been defined. |
DOI | 10.1111/j.1478-3231.2011.02678.x |
Alternate Journal | Liver Int |
PubMed ID | 22136310 |